197 related articles for article (PubMed ID: 16835303)
1. Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF.
Qin G; Kishore R; Dolan CM; Silver M; Wecker A; Luedemann CN; Thorne T; Hanley A; Curry C; Heyd L; Dinesh D; Kearney M; Martelli F; Murayama T; Goukassian DA; Zhu Y; Losordo DW
Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11015-20. PubMed ID: 16835303
[TBL] [Abstract][Full Text] [Related]
2. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.
Merdzhanova G; Gout S; Keramidas M; Edmond V; Coll JL; Brambilla C; Brambilla E; Gazzeri S; Eymin B
Oncogene; 2010 Sep; 29(39):5392-403. PubMed ID: 20639906
[TBL] [Abstract][Full Text] [Related]
3. E2F1 suppresses cardiac neovascularization by down-regulating VEGF and PlGF expression.
Wu M; Zhou J; Cheng M; Boriboun C; Biyashev D; Wang H; Mackie A; Thorne T; Chou J; Wu Y; Chen Z; Liu Q; Yan H; Yang Y; Jie C; Tang YL; Zhao TC; Taylor RN; Kishore R; Losordo DW; Qin G
Cardiovasc Res; 2014 Dec; 104(3):412-22. PubMed ID: 25341896
[TBL] [Abstract][Full Text] [Related]
4. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma.
Pal S; Datta K; Mukhopadhyay D
Cancer Res; 2001 Sep; 61(18):6952-7. PubMed ID: 11559575
[TBL] [Abstract][Full Text] [Related]
5. p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex.
Zhou Z; Cao JX; Li SY; An GS; Ni JH; Jia HT
Exp Cell Res; 2013 Dec; 319(20):3104-15. PubMed ID: 24076372
[TBL] [Abstract][Full Text] [Related]
6. Transcription factor NF-Y induces apoptosis in cells expressing wild-type p53 through E2F1 upregulation and p53 activation.
Gurtner A; Fuschi P; Martelli F; Manni I; Artuso S; Simonte G; Ambrosino V; Antonini A; Folgiero V; Falcioni R; Sacchi A; Piaggio G
Cancer Res; 2010 Dec; 70(23):9711-20. PubMed ID: 20952509
[TBL] [Abstract][Full Text] [Related]
7. E2F1 Hinders Skin Wound Healing by Repressing Vascular Endothelial Growth Factor (VEGF) Expression, Neovascularization, and Macrophage Recruitment.
Wang N; Wu Y; Zeng N; Wang H; Deng P; Xu Y; Feng Y; Zeng H; Yang H; Hou K; Wang A; Parthasarathy K; Goyal S; Qin G; Wu M
PLoS One; 2016; 11(8):e0160411. PubMed ID: 27490344
[TBL] [Abstract][Full Text] [Related]
8. E2F1-dependent pathways are involved in amonafide analogue 7-d-induced DNA damage, G2/M arrest, and apoptosis in p53-deficient K562 cells.
Li Y; Shao J; Shen K; Xu Y; Liu J; Qian X
J Cell Biochem; 2012 Oct; 113(10):3165-77. PubMed ID: 22593008
[TBL] [Abstract][Full Text] [Related]
9. MEF/ELF4 transactivation by E2F1 is inhibited by p53.
Taura M; Suico MA; Fukuda R; Koga T; Shuto T; Sato T; Morino-Koga S; Okada S; Kai H
Nucleic Acids Res; 2011 Jan; 39(1):76-88. PubMed ID: 20805247
[TBL] [Abstract][Full Text] [Related]
10. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.
Fontemaggi G; Dell'Orso S; Trisciuoglio D; Shay T; Melucci E; Fazi F; Terrenato I; Mottolese M; Muti P; Domany E; Del Bufalo D; Strano S; Blandino G
Nat Struct Mol Biol; 2009 Oct; 16(10):1086-93. PubMed ID: 19783986
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1.
Zhou D; Masri S; Ye JJ; Chen S
Gene; 2005 Nov; 361():89-100. PubMed ID: 16181749
[TBL] [Abstract][Full Text] [Related]
12. RBM38 is a direct transcriptional target of E2F1 that limits E2F1-induced proliferation.
Feldstein O; Ben-Hamo R; Bashari D; Efroni S; Ginsberg D
Mol Cancer Res; 2012 Sep; 10(9):1169-77. PubMed ID: 22798430
[TBL] [Abstract][Full Text] [Related]
13. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network.
Menendez D; Krysiak O; Inga A; Krysiak B; Resnick MA; Schönfelder G
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1406-11. PubMed ID: 16432214
[TBL] [Abstract][Full Text] [Related]
14. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE
Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082
[TBL] [Abstract][Full Text] [Related]
15. The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1.
Ou YH; Chung PH; Hsu FF; Sun TP; Chang WY; Shieh SY
EMBO J; 2007 Sep; 26(17):3968-80. PubMed ID: 17690688
[TBL] [Abstract][Full Text] [Related]
16. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway.
Russell JL; Weaks RL; Berton TR; Johnson DG
Oncogene; 2006 Feb; 25(6):867-76. PubMed ID: 16205640
[TBL] [Abstract][Full Text] [Related]
17. E2F1 enhances glycolysis through suppressing Sirt6 transcription in cancer cells.
Wu M; Seto E; Zhang J
Oncotarget; 2015 May; 6(13):11252-63. PubMed ID: 25816777
[TBL] [Abstract][Full Text] [Related]
18. E2F regulates DDB2: consequences for DNA repair in Rb-deficient cells.
Prost S; Lu P; Caldwell H; Harrison D
Oncogene; 2007 May; 26(24):3572-81. PubMed ID: 17173070
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional and post-transcriptional mechanisms for oncogenic overexpression of ether à go-go K+ channel.
Lin H; Li Z; Chen C; Luo X; Xiao J; Dong D; Lu Y; Yang B; Wang Z
PLoS One; 2011; 6(5):e20362. PubMed ID: 21655246
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis.
Sayeed A; Konduri SD; Liu W; Bansal S; Li F; Das GM
Cancer Res; 2007 Aug; 67(16):7746-55. PubMed ID: 17699779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
